Shortage of Contrast for Imaging Services

Because of a global shortage of iodinated contrast material (Omnipaque) caused by temporary overseas manufacturing disruptions, ChristianaCare is taking steps to preserve supply so that it remains available for the most time-sensitive and urgent patient needs. (Learn more in our frequently asked questions.)

Omnipaque contrast is the most widely used contrast material for CT scans and radiographic examinations at ChristianaCare facilities. It is also used for cardiac imaging and interventions, and in the GI lab, Surgicenter and other settings.

The shortage is expected to last several weeks, and likely into the summer months.

Hospitals and health care organizations worldwide are managing the effects of the shortage and the impact to patient care.

ChristianaCare is making every effort to meet the needs of patients who need this product in their procedures. We are working individually with physicians to prioritize those patients with the most urgent needs.

Wherever possible, we are using alternative contrast material and limiting its use to ensure adequate supplies for time sensitive and emergent exams. It is possible that some elective procedures that use this product will need to be delayed.

ChristianaCare will continue to look for options to minimize disruptions created by the shortage, as we serve our community as expert, caring partners in health.

Learn more in our frequently asked questions (FAQs).

COVID-19: New Visitation Guidelines. Click here for what to expect at ChristianaCare during COVID-19.

ChristianaCare

Shortage of Contrast for Imaging Services

Because of a global shortage of iodinated contrast material (Omnipaque) caused by temporary overseas manufacturing disruptions, ChristianaCare is taking steps to preserve supply so that it remains available for the most time-sensitive and urgent patient needs. (Learn more in our frequently asked questions.)

Omnipaque contrast is the most widely used contrast material for CT scans and radiographic examinations at ChristianaCare facilities. It is also used for cardiac imaging and interventions, and in the GI lab, Surgicenter and other settings.

The shortage is expected to last several weeks, and likely into the summer months.

Hospitals and health care organizations worldwide are managing the effects of the shortage and the impact to patient care.

ChristianaCare is making every effort to meet the needs of patients who need this product in their procedures. We are working individually with physicians to prioritize those patients with the most urgent needs.

Wherever possible, we are using alternative contrast material and limiting its use to ensure adequate supplies for time sensitive and emergent exams. It is possible that some elective procedures that use this product will need to be delayed.

ChristianaCare will continue to look for options to minimize disruptions created by the shortage, as we serve our community as expert, caring partners in health.

Learn more in our frequently asked questions (FAQs).

COVID-19: New Visitation Guidelines. Click here for what to expect at ChristianaCare during COVID-19.

Breast Cancer Research Program at the
Helen F. Graham Cancer Center
& Research Institute

Breast Cancer Research Program Members

 

Leadership

Jennifer Sims-Mourtada, Ph.D, Translational Director
Pat Swanson, BSN, Administrative Director

Members

Collectively our expertise covers medical, radiation and surgical oncology, pathology, psychology, medical genetics, cellular signaling, molecular biology, immunology, chemical engineering, nanotechnology, epidemiology, outreach and supportive care.

Helen F. Graham Cancer Center & Research Institute

Zohra Ali-Khan Catts, MS, LCGC, director, Cancer Genetic Counseling
Nora Katurakes, MSN, RN, OCN, manager, Community Health Outreach & Education
Lindsay Romak, M.D., radiation oncologist
Scott Siegel, PhD, director, Population Health Research
Ramya Varadarajan, M.D., medical oncologist
Shannon Virtue, PhD, psychologist

University of Delaware

Emily Day, Ph.D., assistant professor, biomedical engineering
April Kloxin, Ph.D., assistant professor, joint professor, materials science and engineering.
John Slater, Ph.D., assistant professor, biomedical engineering.
Kenneth van Golen, Ph.D., associate professor, biological sciences.

The Wistar Institute

Maureen Murphy, Ph.D., professor and program leader, molecular & cellular ongogenesis.
Zachary Schug, Ph.D., assistant professor, molecular & cellular ongogenesis.

Cancer Research Program
Helen F. Graham Cancer Center & Research Institute
4701 Ogletown-Stanton Road, Suite 2200, Newark, DE 19713 directions
For more information, call 302-623-4450 or e-mail us.